Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Update

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) saw a significant increase in short interest in October. As of October 31st, there was short interest totalling 5,100,000 shares, an increase of 7.8% from the October 15th total of 4,730,000 shares. Currently, 25.2% of the shares of the stock are sold short. Based on an average daily volume of 191,600 shares, the days-to-cover ratio is currently 26.6 days.

Hedge Funds Weigh In On Dianthus Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Quest Partners LLC raised its position in shares of Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after purchasing an additional 1,124 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Dianthus Therapeutics during the second quarter worth about $112,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Dianthus Therapeutics during the second quarter worth about $236,000. Fred Alger Management LLC raised its position in shares of Dianthus Therapeutics by 52.5% during the third quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock worth $264,000 after purchasing an additional 3,316 shares during the period. Finally, WINTON GROUP Ltd acquired a new stake in shares of Dianthus Therapeutics during the second quarter worth about $265,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Price Performance

NASDAQ:DNTH opened at $23.60 on Tuesday. Dianthus Therapeutics has a 1-year low of $6.58 and a 1-year high of $33.77. The business’s 50-day moving average price is $27.50 and its two-hundred day moving average price is $26.70.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.07 million. Analysts predict that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Analysts Set New Price Targets

DNTH has been the topic of a number of recent analyst reports. Baird R W raised Dianthus Therapeutics to a “strong-buy” rating in a research note on Friday, July 26th. Raymond James boosted their target price on Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Oppenheimer boosted their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research report on Monday, November 11th. Finally, Robert W. Baird assumed coverage on Dianthus Therapeutics in a research report on Friday, July 26th. They set an “outperform” rating and a $58.00 target price for the company. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Dianthus Therapeutics currently has an average rating of “Buy” and an average target price of $46.43.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.